Tue.Jan 16, 2024

article thumbnail

Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia

Fierce Pharma

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FD | Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date.

FDA 306
article thumbnail

Vertex’s CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease

MedCity News

The FDA approved Vertex Pharmaceuticals’ gene therapy Casgevy for treating beta thalassemia, an inherited blood disease that leads to low levels of functioning hemoglobin. Last month, the one-time treatment won its first FDA nod for treating sickle cell disease.

FDA 134
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GSK pumps £200M+ into UK manufacturing network to bolster commercial ambitions, API supply

Fierce Pharma

As British pharma giant AstraZeneca looks abroad to build new factories, GSK is sticking close to home, where it plans to plug hundreds of millions of pounds into the United Kingdom over the next t | As other British drugmakers like AstraZeneca look abroad to build new factories, GSK is sticking close to home, where it plans to plug hundreds of millions of pounds into the United Kingdom over the next two years.

article thumbnail

5 Ways Google Is Protecting Kids’ Mental Health on YouTube

MedCity News

During a session at CES 2024, a Google exec shared several changes the company has made through YouTube to protect children and teens.

Media 133
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Takeda picks up 2nd FDA-approved indication for immune globulin treatment HyQvia

Fierce Pharma

The FDA has approved Takeda's HyQvia as a maintenance therapy for CIDP. It is the second indication for HyQvia, which was first endorsed in 2014.

FDA 290
article thumbnail

Boulder Care Extends Virtual Substance Use Disorder Treatment to Adolescents

MedCity News

As the opioid crisis grows for teens, Boulder Care has expanded its substance use disorder treatment to support adolescents. The company is starting its adolescent services in Washington with UnitedHealthcare Community Plan.

128
128

More Trending

article thumbnail

More Than a Survey: How to Holistically Embrace the Patient Experience

MedCity News

Despite the challenges that healthcare providers face and declining patient experience scores, several effective strategies can enhance their work to improve the patient experience and sufficiently satisfy expectations for care.

Patients 128
article thumbnail

In biopharma, employees at Novartis, GSK, AZ and Genentech are most satisfied with their compensation: analysis

Fierce Pharma

2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. | A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields. Novartis, GSK, AstraZeneca and Genentech stood out in the reviews, according to the report.

Biopharma 264
article thumbnail

Allakos Skin Drug Fails 2 Mid-Stage Tests, Sparks Restructuring to Cut 50% of Staff

MedCity News

Allakos’s lirentelimab did not beat a placebo in separate Phase 2 tests in atopic dermatitis and spontaneous chronic urticaria. A restructuring now turns the biotech’s focus to an early-stage drug candidate also designed to treat inflammation.

Biopharma 123
article thumbnail

Prominent German trade union pushes back on potential Bayer split: Reuters

Fierce Pharma

As Bayer’s new CEO Bill Anderson kicks off his first full year at the helm with an objective to revamp the company, a prominent German trade union is pressing to keep the large conglomerate togethe | As new CEO Bill Anderson presses on with his strategic review, Germany's IG BCE is taking issue with potential German job losses that could stem from a long-rumored split of Bayer's three segments, Reuters reports.

246
246
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

DISCO dances out of the shadows with €20m for ‘surfaceome’

pharmaphorum

DISCO Pharma has emerged from stealth with €20m in seed financing that will be used to advance its surfaceome cancer target-hunting platform

Pharma 115
article thumbnail

Lonza plots more than 200 layoffs at clinical manufacturing site in California

Fierce Pharma

Just a few months after Lonza unveiled hundreds of new hires, the Swiss CDMO juggernaut is telegraphing nearly as many layoffs in California. | Lonza is axing 218 jobs at its site in Alameda County, California, according to a new Worker Adjustment and Retraining Notification (WARN) alert. The cuts come as Lonza plans hundreds of hires in Switzerland.

article thumbnail

Pharma takes a gut check of microbiome drugs

PharmaVoice

On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

Pharma 111
article thumbnail

Innovaccer Acquires Cured to Enhance Its Patient Engagement Strategy

MedCity News

Innovaccer acquired Cured, a healthcare digital marketing and CRM platform. With the deal, Innovaccer gains more than 20 customers to add to its current portfolio of clients. Innovaccer CEO Abhinav Shashank said the main goal of the acquisition was to help his company become a leader in patient experience technology.

CRM 111
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Roche bags EU okay for subcutaneous Tecentriq

pharmaphorum

Roche’s Tecentriq has become the first PD-1/PD-L1 inhibitor to be cleared in the EU in a subcutaneous form that will make dosing easier for patients and healthcare providers

article thumbnail

The Benefits and Privacy Concerns in Utilizing Artificial Intelligence for Early Detection of Breast Cancer

Pharmaceutical Commerce

Cureus report discuss the value of AI, but the medical community must remain aware of privacy pitfalls.

Medical 103
article thumbnail

Roche cancer immunotherapy receives new EU approval

European Pharmaceutical Review

The European Commission (EC) has approved the EU’s first PD-(L)1 cancer immunotherapy for subcutaneous injection. Roche’s Tecentriq ® (atezolizumab) was first approved in Great Britain in August 2023. Compared with standard intravenous (IV) delivery, Roche stated that its monoclonal antibody biologic shortens treatment time by approximately 80 percent.

Medical 98
article thumbnail

AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development

PharmaTech

CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.

98
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

XNK Therapeutics’ Evencaleucel gains EMA recommendation

Pharmaceutical Technology

XNK Therapeutics has received scientific recommendation from the EMA's Committee for Advanced Therapies (CAT) for its product evencaleucel.

98
article thumbnail

Aston University receives £10m for membrane institute

PharmaTimes

Aston University to create the Aston Institute for Membrane Excellence

88
article thumbnail

Google chatbot tops docs on accuracy, bedside manner

pharmaphorum

Medical chatbot designed by Google and DeepMind outperformed doctors on accuracy and empathy in a study but is a long way from being ready for real-world use

Doctors 69
article thumbnail

Disco tunes into new cancer drug targets

PharmaTimes

EUR 20m to identify new targets and develop first in class drugs

85
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

IRA lawsuits will test US’ ability to regulate social pricing in pharma

Pharmaceutical Technology

As the deadline nears for the government to reveal its proposed prices, pharmaceutical companies are continuing to fight regulation.

article thumbnail

To Crush or Not to Crush: That is the Medication Administration Question

Pharmacy Times

Pharmacists are well suited to identify patients with dysphagia and educate patients and caregivers on when and how to safely crush and administer medication.

Medical 63
article thumbnail

Roche’s Tecentriq SC receives EC approval for cancer treatment

Pharmaceutical Technology

Roche has received marketing authorisation from the EC for Tecentriq SC for subcutaneous administration to treat cancers.

article thumbnail

Community Pharmacists Have Distinct Role in Fall Prevention for Patients

Pharmacy Times

Pharmacists play a significant role in early identification, continuous monitoring, and interventions to help minimize the risk of falls in older adults.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Contract Packaging Set for High Growth in 2024

PharmaTech

According to the Pharmapack Europe 2024 survey results, contract packaging will see growth over the coming 12 months.

59
article thumbnail

FDA chief says agency can’t manage health tech alone

PharmaVoice

FDA Commissioner Dr. Robert Califf recently spoke about the future of AI and machine learning and the need for constant vigilance to improve healthcare systems.

FDA 59
article thumbnail

FDA Approves IgG-Hyaluronidase Recombinant for the Treatment of Adult Patients With CIDP

Pharmacy Times

Previously, IgG-hyaluronidase recombinant was approved by the FDA in 2014 for the treatment of primary immunodeficiency in adult patients and has expanded to include some pediatric patients.

FDA 58
article thumbnail

Your 2024 Legal Vision Board: Trends and Opportunities for Digital Health Innovators

Nixon Gwilt Law

What can digital health innovators and investors anticipate for the industry in 2024? We asked our team to share their insights on healthcare innovation, new regulations, and trends we expect to impact your business this year. As a nationally recognized law firm exclusively dedicated to advancing the future of healthcare, Nixon Law Group attorneys think like the innovators they serve.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A